| scholarly article | Q13442814 |
| P356 | DOI | 10.1146/ANNUREV-PHARMTOX-010715-103111 |
| P698 | PubMed publication ID | 26514196 |
| P50 | author | Michael M. Gottesman | Q6832389 |
| P2093 | author name string | Jean-Pierre Gillet | |
| Orit Lavi | |||
| Matthew D Hall | |||
| P2860 | cites work | Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation | Q24629474 |
| Mutations of the BRAF gene in human cancer | Q27860760 | ||
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 85-102 | |
| P577 | publication date | 2015-10-28 | |
| P1433 | published in | Annual Review of Pharmacology and Toxicology | Q567365 |
| P1476 | title | Toward a Better Understanding of the Complexity of Cancer Drug Resistance | |
| P478 | volume | 56 |
| Q90083275 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein |
| Q37718215 | A piRNA-like Small RNA Induces Chemoresistance to Cisplatin-Based Therapy by Inhibiting Apoptosis in Lung Squamous Cell Carcinoma |
| Q92961815 | Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma |
| Q38557650 | Applying nanomedicine in maladaptive inflammation and angiogenesis |
| Q42371843 | Assessing inhibitors of mutant isocitrate dehydrogenase using a suite of pre-clinical discovery assays |
| Q48112768 | CRISPR-Cas9-mediated saturated mutagenesis screen predicts clinical drug resistance with improved accuracy |
| Q46900302 | Cancer Immunotherapy Getting Brainy: Visualizing the Distinctive CNS Metastatic Niche to Illuminate Therapeutic Resistance. |
| Q92703787 | Cancer Stem Cells and Targeting Strategies |
| Q97643334 | Chemical strategies to overcome resistance against targeted anticancer therapeutics |
| Q92701884 | Deep Sequencing Analysis Reveals Distinctive Non-Coding RNAs When Comparing Tumor Multidrug-Resistant Cells and Extracellular Vesicles with Drug-Sensitive Counterparts |
| Q92156719 | Drug combination sensitivity scoring facilitates the discovery of synergistic and efficacious drug combinations in cancer |
| Q91844985 | DrugComb: an integrative cancer drug combination data portal |
| Q90334544 | Effects of Natural Polyphenols on the Expression of Drug Efflux Transporter P-Glycoprotein in Human Intestinal Cells |
| Q39603486 | Emergent properties of a computational model of tumour growth |
| Q95840696 | Epoxylathyrane Derivatives as MDR-Selective Compounds for Disabling Multidrug Resistance in Cancer |
| Q92408754 | European mtDNA Variants Are Associated With Differential Responses to Cisplatin, an Anticancer Drug: Implications for Drug Resistance and Side Effects |
| Q95276446 | Exosomal MicroRNA-221-3p Confers Adriamycin Resistance in Breast Cancer Cells by Targeting PIK3R1 |
| Q37564876 | Exploring conformational equilibria of a heterodimeric ABC transporter. |
| Q52670051 | Identification of COL4A1 as a potential gene conferring trastuzumab resistance in gastric cancer based on bioinformatics analysis. |
| Q49382862 | Immunological hallmarks of cis-DDP-resistant Lewis lung carcinoma cells. |
| Q36125103 | Inhibition of never in mitosis A (NIMA)-related kinase-4 reduces survivin expression and sensitizes cancer cells to TRAIL-induced cell death |
| Q55656421 | Integrative Analysis of Dysregulated lncRNA-Associated ceRNA Network Reveals Functional lncRNAs in Gastric Cancer. |
| Q92382750 | Knockdown of lncRNA MIAT inhibits proliferation and cisplatin resistance in non-small cell lung cancer cells by increasing miR-184 expression |
| Q55282022 | Leptin-Notch axis impairs 5-fluorouracil effects on pancreatic cancer. |
| Q50076078 | Leveraging Chemotype-Specific Resistance for Drug Target Identification and Chemical Biology |
| Q97569963 | LncRNA PSMA3-AS1 Promotes Lung Cancer Growth and Invasion via Sponging MiR-4504 |
| Q58608801 | Machine learning predicts individual cancer patient responses to therapeutic drugs with high accuracy |
| Q60912359 | Mechanisms of Matrix-Induced Chemoresistance of Breast Cancer Cells-Deciphering Novel Potential Targets for a Cell Sensitization |
| Q93017361 | Microtubule-targeting anticancer drug eribulin induces drug efflux transporter P-glycoprotein |
| Q42798231 | Molecular Imaging of P-glycoprotein in Chemoresistant Tumors Using a Dual-Modality PET/Fluorescence Probe. |
| Q100534618 | Molecular and cellular paradigms of multidrug resistance in cancer |
| Q90608550 | N6-methyladenosine-induced ERRγ triggers chemoresistance of cancer cells through upregulation of ABCB1 and metabolic reprogramming |
| Q33772186 | Nanoparticle-based drug delivery systems: What can they really do in vivo? |
| Q57033051 | P-Glycoprotein-Targeted Photothermal Therapy of Drug-Resistant Cancer Cells Using Antibody-Conjugated Carbon Nanotubes |
| Q57287520 | P-glycoprotein targeted photodynamic therapy of chemoresistant tumors using recombinant Fab fragment conjugates |
| Q60930267 | P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment |
| Q64279888 | PYK2 promotes HER2-positive breast cancer invasion |
| Q37624466 | Paclitaxel-resistant cancer cell-derived secretomes elicit ABCB1-associated docetaxel cross-resistance and escape from apoptosis through FOXO3a-driven glycolytic regulation |
| Q39820811 | Pharmacological Development of Target-Specific Delocalized Lipophilic Cation-Functionalized Carboranes for Cancer Therapy |
| Q94545721 | Phenotypic screening using large-scale genomic libraries to identify drug targets for the treatment of cancer |
| Q52343895 | Poly-ligand profiling differentiates trastuzumab-treated breast cancer patients according to their outcomes. |
| Q92533682 | Polytherapy and Targeted Cancer Drug Resistance |
| Q89824200 | Prior acquired resistance to paclitaxel relays diverse EGFR-targeted therapy persistence mechanisms |
| Q38918710 | Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification |
| Q92127589 | Proteomic Analysis of Breast Cancer Resistance to the Anticancer Drug RH1 Reveals the Importance of Cancer Stem Cells |
| Q48246978 | Recent advances in the biology and therapy of medullary thyroid carcinoma. |
| Q88404555 | Reversion of Multidrug Resistance by Co-Encapsulation of Doxorubicin and Metformin in Poly(lactide-co-glycolide)-d-α-tocopheryl Polyethylene Glycol 1000 Succinate Nanoparticles |
| Q52593092 | Revisiting the role of ABC transporters in multidrug-resistant cancer. |
| Q55465529 | Short- and long-term evolution in our arms race with cancer: Why the war on cancer is winnable. |
| Q64073261 | Structure and Anti-Tumor Activities of Exopolysaccharides from Roberts |
| Q64912838 | TNF-α Modulates P-Glycoprotein Expression and Contributes to Cellular Proliferation via Extracellular Vesicles. |
| Q48168156 | Targeting P-glycoprotein and SORCIN: Dihydromyricetin strengthens anti-proliferative efficiency of adriamycin via MAPK/ERK and Ca2+ -mediated apoptosis pathways in MCF-7/ADR and K562/ADR. |
| Q37702768 | Targeting P-glycoprotein function, p53 and energy metabolism: Combination of metformin and 2-deoxyglucose reverses the multidrug resistance of MCF-7/Dox cells to doxorubicin |
| Q58773220 | Th1-Biased Immunomodulation and In Vivo Antitumor Effect of a Novel Piperine Analogue |
| Q60914167 | The Adaptive Complexity of Cancer |
| Q90303582 | The Emerging Role of the SLCO1B3 Protein in Cancer Resistance |
| Q58694197 | The Network of Non-coding RNAs in Cancer Drug Resistance |
| Q39196784 | The therapeutic potential of targeting ABC transporters to combat multi-drug resistance. |
| Q96576495 | Theoretical insights on helix repacking as the origin of P-glycoprotein promiscuity |
| Q47216949 | Towards Comprehension of the ABCB1/P-Glycoprotein Role in Chronic Myeloid Leukemia |
| Q91906475 | Transcription factor Nrf2 induces the up-regulation of lncRNA TUG1 to promote progression and adriamycin resistance in urothelial carcinoma of the bladder |
| Q33754032 | microRNA-200a-3p increases 5-fluorouracil resistance by regulating dual specificity phosphatase 6 expression |
Search more.